Episurf Medical has planned the 600th surgery with the Episealer® implant. This is an increase from 500 procedures, as reported in 1Q19.
The company recently reported that more than 100 Episealer patients have had their knee implants for more than three years, and more than 200 patients have had them for more than two years.
Chief Executive Officer Pål Ryfors noted that patients and surgeons are demanding alternative treatments to treat damaged joints, saying, “Establishing a new technology as a new standard in this market segment comes with a great burden of proof. That’s all expected. But what we can say, it that what is being asked for from us, we are delivering. More and more surgeons are adopting this new technology, and we are in constant dialogue with a vast number of potential users. We are still at the beginning of our establishment, but we have come this far with minimal clinical evidence. I am very excited about the steps we will be able to take as more evidence is available and as we execute on our strategy.”
Episurf Medical has planned the 600th surgery with the Episealer® implant. This is an increase from 500 procedures, as reported in 1Q19.
The company recently reported that more than 100 Episealer patients have had their knee implants for more than three years, and more than 200 patients have had them for more than two years.
Chief Executive...
Episurf Medical has planned the 600th surgery with the Episealer® implant. This is an increase from 500 procedures, as reported in 1Q19.
The company recently reported that more than 100 Episealer patients have had their knee implants for more than three years, and more than 200 patients have had them for more than two years.
Chief Executive Officer Pål Ryfors noted that patients and surgeons are demanding alternative treatments to treat damaged joints, saying, “Establishing a new technology as a new standard in this market segment comes with a great burden of proof. That’s all expected. But what we can say, it that what is being asked for from us, we are delivering. More and more surgeons are adopting this new technology, and we are in constant dialogue with a vast number of potential users. We are still at the beginning of our establishment, but we have come this far with minimal clinical evidence. I am very excited about the steps we will be able to take as more evidence is available and as we execute on our strategy.”
Copy to clipboard 
